CDER Says Keeping Avastin Breast Cancer Claim Would Undermine Accelerated Approval Process
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Center for Drug Evaluation and Research intends to argue at a June hearing that the accelerated approval system will operate as a lower standard if bevacizumab's breast cancer indication is maintained while Genentech conducts another confirmatory trial.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: